Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STR-P004 in Relapsed or Refractory Autoimmune Diseases
NCT07143617Recruiting
- Sponsor
- Beijing Gaobo Hospital
- Start
- Sep 2025
- Primary completion
- Aug 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Open-label trial of STR-P004 in systemic lupus erythematosus (SLE) and idiopathic inflammatory myopathy (IIM) (3 arms), sponsored by Beijing Gaobo Hospital. Primary endpoints: Dose-limiting toxicity at 12 months and Adverse Events and Serious Adverse Events at 12 months. Started Sep 2025; status: recruiting.
02
Drugs
STR-P004
03
Conditions
systemic lupus erythematosus (SLE)idiopathic inflammatory myopathy (IIM)
Beyond the preview
Go deeper on NCT07143617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07143617.